IE861917L - Tertiary hydroxyalkylxanthines - Google Patents

Tertiary hydroxyalkylxanthines

Info

Publication number
IE861917L
IE861917L IE861917A IE191786A IE861917L IE 861917 L IE861917 L IE 861917L IE 861917 A IE861917 A IE 861917A IE 191786 A IE191786 A IE 191786A IE 861917 L IE861917 L IE 861917L
Authority
IE
Ireland
Prior art keywords
pct
carbon atoms
tertiary
sec
image
Prior art date
Application number
IE861917A
Other versions
IE59025B1 (en
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of IE861917L publication Critical patent/IE861917L/en
Publication of IE59025B1 publication Critical patent/IE59025B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Abstract

PCT No. PCT/EP86/00401 Sec. 371 Date Mar. 16, 1987 Sec. 102(e) Date Mar. 16, 1987 PCT Filed Jul. 8, 1986 PCT Pub. No. WO87/00523 PCT Pub. Date Jan. 29, 1987.Tertiary hydroxyalkylxanthines having the general formula (I), characterized by the fact that at least one of the residues R1 and R3 represents a tertiary hydroxyalkyl group of formula (Ia) in which R4 represents an alkyl group having up to 3 carbon atoms and n a whole number from 2 to 5; the other residue which may remain R1 or R3 is a hydrogen atom or an aliphatic hydrocarbon residue R5 having up to 6 carbon atoms, in which the carbon chain may be separated by a maximum of two oxygen atoms or be substituted by an oxo group or two hydroxy groups at the most, and R2 represents an alkyl group with 1 to 4 carbon atoms. Also described is a process for manufacturing these compounds, which are suitable for the manufacture of medicines, in particular for use in the prevention and/or treatment of peripheral and/or cerebral irrigation disorders. <IMAGE> (I) <IMAGE> (Ia) [US4833146A]
IE191786A 1985-07-19 1986-07-18 Tertiary hydroxyalkylxanthines, process for their preparation, medicaments containing them and their use IE59025B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19853525801 DE3525801A1 (en) 1985-07-19 1985-07-19 TERTIA HYDROXYALKYLXANTHINE, METHOD FOR THE PRODUCTION THEREOF, THE MEDICINAL PRODUCT CONTAINING IT AND THEIR USE

Publications (2)

Publication Number Publication Date
IE861917L true IE861917L (en) 1987-01-19
IE59025B1 IE59025B1 (en) 1993-12-15

Family

ID=6276182

Family Applications (1)

Application Number Title Priority Date Filing Date
IE191786A IE59025B1 (en) 1985-07-19 1986-07-18 Tertiary hydroxyalkylxanthines, process for their preparation, medicaments containing them and their use

Country Status (33)

Country Link
US (1) US4833146A (en)
EP (1) EP0268585B1 (en)
JP (1) JPH0788382B2 (en)
KR (1) KR950001019B1 (en)
CN (1) CN1026112C (en)
AR (1) AR244689A1 (en)
AT (1) ATE53211T1 (en)
AU (1) AU588350B2 (en)
BG (1) BG60767B2 (en)
CA (1) CA1262248A (en)
CS (1) CS272766B2 (en)
DD (1) DD261156A5 (en)
DE (2) DE3525801A1 (en)
DK (1) DK157867C (en)
ES (1) ES2001019A6 (en)
FI (1) FI89921C (en)
GR (1) GR861866B (en)
HU (1) HU198486B (en)
IE (1) IE59025B1 (en)
IL (1) IL79457A0 (en)
LT (1) LT3869B (en)
LV (1) LV5703A3 (en)
MA (1) MA20739A1 (en)
MX (1) MX9254A (en)
NO (1) NO165803C (en)
NZ (1) NZ216888A (en)
OA (1) OA08707A (en)
PH (1) PH26262A (en)
PT (1) PT83013B (en)
RU (1) RU2051918C1 (en)
TN (1) TNSN86111A1 (en)
WO (1) WO1987000523A2 (en)
ZA (1) ZA865374B (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8621870D0 (en) * 1986-09-11 1986-10-15 Beecham Group Plc Active compounds
US5338741A (en) * 1986-10-27 1994-08-16 Nestec S.A. 1-hydroxyalkylxanthines and medicaments containing them
JP2661666B2 (en) * 1988-02-19 1997-10-08 ヘキスト薬品工業株式会社 Anti-peptic ulcer agent
GB8826595D0 (en) * 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
DD298051A5 (en) * 1989-08-16 1992-02-06 ��@���������@�������k�� PROCESS FOR THE PREPARATION OF A THERAPEUTIC AGENT FOR THE TREATMENT OF DIGESTIVE DISEASES
GB8924392D0 (en) * 1989-10-30 1989-12-20 Bayer Ag Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides
EP0430300A3 (en) * 1989-12-01 1992-03-25 Takeda Chemical Industries, Ltd. Xanthine derivatives, their production and use
DE3942872A1 (en) * 1989-12-23 1991-06-27 Hoechst Ag METHOD FOR THE ENANTIOSELECTIVE PRESENTATION OF ((OMEGA) -1) -HYDROXYALKYLXANTHINES
IT1240843B (en) * 1990-05-24 1993-12-17 Malesci Istituto Farmacobiologico XANTHINIC DERIVATIVES 1-7 SUBSTITUTED FOR ANTIASMATIC ACTIVITY, THEIR PHYSIOLOGICALLY ACCEPTABLE SALTS, THEIR PHARMACEUTICAL COMPOSITIONS AND PROCEDURE FOR THEIR PREPARATION.
DE4019892A1 (en) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg New xanthine derivs. are selective A1 adenosine antagonists - useful for treating CNS disorders (e.g. senile dementia) and heart and circulation disorders
US5039666A (en) * 1990-10-30 1991-08-13 Hoechst-Roussel Pharmaceuticals Inc. Aminoglycoside composition having substantially reduced nephrotoxicity induced by the aminoglycoside
DK0484785T3 (en) * 1990-11-07 1996-09-23 Hoechst Marion Roussel Inc Use of xanthines for the preparation of a drug effective in inhibiting the proliferation of human retroviruses
US6420374B1 (en) 1990-11-30 2002-07-16 Fred Hutchinson Cancer Research Center Use of xanthines as immunosuppressants and to inhibit allograft reactions
MX9203323A (en) * 1991-07-11 1994-07-29 Hoechst Ag THE USE OF XANTHINE DERIVATIVES FOR THE TREATMENT OF SECONDARY INJURIES OF THE NERVOUS CELLS AND FUNCTIONAL DISORDERS AFTER CRANIAL-BRAIN TRAUMA.
TW209834B (en) * 1991-12-11 1993-07-21 Hoechst Ag
DE59304710D1 (en) * 1992-02-22 1997-01-23 Hoechst Ag Use of xanthine derivatives to treat muscle damage after the blood circulation has been completely interrupted
DK0584347T3 (en) * 1992-03-04 2003-02-24 Cell Therapeutics Inc Enantiomeric hydroxylated xanthine compounds
EP0570831A2 (en) * 1992-05-20 1993-11-24 Hoechst Aktiengesellschaft Use of Xanthinderivatives for treatment of cerebral nerve dammages after disruption of the blood circulation
US5288721A (en) * 1992-09-22 1994-02-22 Cell Therapeutics, Inc. Substituted epoxyalkyl xanthines
US5817662A (en) * 1992-11-09 1998-10-06 Cell Therapeutics, Inc. Substituted amino alkyl compounds
US5473070A (en) * 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
US6693105B1 (en) 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US5804584A (en) * 1992-11-16 1998-09-08 Cell Therapeutics, Inc. Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms
US5866576A (en) * 1992-12-16 1999-02-02 Cell Therapeutics, Inc. Epoxide-containing compounds
AU6087894A (en) * 1993-01-14 1994-08-15 Cell Therapeutics, Inc. Acetal or ketal substituted therapeutic compounds
WO1994016704A1 (en) * 1993-01-19 1994-08-04 Cell Therapeutics, Inc. Oxime-substituted therapeutic compounds
US5641783A (en) * 1993-11-12 1997-06-24 Cell Therapeutics, Inc. Substituted amino alcohol compounds
US5837703A (en) * 1993-03-31 1998-11-17 Cell Therapeutics, Inc. Amino-alcohol substituted cyclic compounds
US6020337A (en) * 1993-04-05 2000-02-01 Cell Therapeutics, Inc. Electronegative-substituted long chain xanthine compounds
AU1831395A (en) * 1994-01-14 1995-08-01 Cell Therapeutics, Inc. Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
WO1995022546A1 (en) * 1994-02-18 1995-08-24 Cell Therapeutics, Inc. Intracellular signalling mediators
US6103730A (en) * 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
US5807861A (en) * 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US5801182A (en) * 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
DE19540798A1 (en) * 1995-11-02 1997-05-07 Hoechst Ag Alkylxanthine phosphonates and alkylxanthine phosphine oxides and their use as medicines
US5965555A (en) * 1996-06-07 1999-10-12 Hoechst Aktiengesellschaft Xanthine compounds having terminally animated alkynol side chains
US5981536A (en) * 1996-07-31 1999-11-09 Hoechst Aktiengesellschaft Use of xanthine derivatives for the modulation of apoptosis
US5856330A (en) * 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
DE19707655A1 (en) * 1997-02-26 1998-08-27 Hoechst Ag Combination preparation for use in dementia
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US5985592A (en) * 1997-06-05 1999-11-16 Dalhousie University Uses for pentoxifylline or functional derivatives/metabolites thereof
US6075029A (en) * 1998-01-02 2000-06-13 Cell Therapeutics, Inc. Xanthine modulators of metabolism of cellular P-450
US20030207901A1 (en) * 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds
DE10042152A1 (en) * 2000-08-26 2002-03-28 Basf Coatings Ag Thixotropic agent that can be activated with actinic radiation, process for its preparation and its use
DE10122390A1 (en) * 2001-05-09 2002-11-28 Basf Coatings Ag Carbamate and / or allophanate-containing, thermally curable, thixotropic mixtures
DE10139262C1 (en) * 2001-08-09 2003-01-02 Basf Coatings Ag A rheological adjuvant, useful for coating materials, adhesives, and sealing compositions, contains a urea derivative obtained by reaction of isocyanate with sterically hindered primary and secondary monoamines
AU2002304685A1 (en) * 2002-04-24 2003-11-10 Basf Coatings Ag Thermally curable, thixotropic mixtures containing carbamate and/or allophanate groups
KR100872788B1 (en) * 2002-05-28 2008-12-09 엘지전자 주식회사 Drum washer
US8686090B2 (en) * 2003-12-10 2014-04-01 Basf Coatings Gmbh Use of urea crystals for non-polymeric coatings
US20080081816A1 (en) * 2006-10-03 2008-04-03 Kaohsiung Medical University Anti-inflammation activity of newly synthesized xanthine derivatives kmup-1 and kmup-3
BRPI0908107A2 (en) * 2008-02-29 2019-09-24 Concert Pharmaceuticals Inc substituted xanthine derivative, pharmaceutical composition comprising such a compound, methods of treating a disease or condition in a patient in need thereof, method of treating chronic kidney disease, liver disease, diabetes-related and intermittent claudication
KR20110014974A (en) * 2008-03-31 2011-02-14 썬 파마슈티컬 인더스트리스 리미티드 An improved process for the preparation of morphinane analogues
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
WO2011028820A1 (en) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
WO2011028835A1 (en) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
WO2012031072A1 (en) 2010-09-01 2012-03-08 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
WO2012031073A1 (en) 2010-09-01 2012-03-08 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
WO2013155465A1 (en) 2012-04-13 2013-10-17 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1245969B (en) * 1967-08-03 VEB Arzneimittelwerk Dresden, Radebeul Process for the production of xanthine derivatives
US2517410A (en) * 1947-08-15 1950-08-01 Searle & Co Hydroxy alkyl xanthines and the production thereof
FR1211333A (en) * 1955-10-19 1960-03-15 Boehringer Sohn Ingelheim Improvements in processes for manufacturing oxyalkylxanthines
US4576947A (en) * 1967-12-16 1986-03-18 Hoechst Aktiengesellschaft Pharmaceutical compositions
DE2335170C2 (en) * 1973-07-11 1989-07-20 Hoechst Ag, 6230 Frankfurt 1,3-Dialkyl-7- (hydroxyalkyl) -xanthines, processes for their preparation and pharmaceuticals containing them
BE795345A (en) * 1972-02-19 1973-08-13 Albert Ag Chem Werke MEDICINAL PRODUCT USEFUL IN PARTICULAR FOR CEREBRAL IRRIGATION, PROCESS FOR THE PREPARATION OF ITS ACTIVE MATERIALS AND THESE MATERIALS ITSELF
CH622519A5 (en) * 1974-07-05 1981-04-15 Hoechst Ag Process for the preparation of hydroxyalkylxanthines
DE2432702C2 (en) * 1974-07-08 1983-01-20 Hoechst Ag, 6000 Frankfurt Process for the preparation of hydroxyalkylxanthines
CA1075690A (en) * 1974-12-13 1980-04-15 Hoechst Aktiengesellschaft Xanthine derivatives
EP0017478B1 (en) * 1979-04-05 1983-03-30 BEECHAM - WUELFING GmbH &amp; Co. KG Dialkoxy- and dioxacycloalkyl-alkyltheobromines, pharmaceutical compositions containing them and their preparation
JPS5838284A (en) * 1981-09-01 1983-03-05 Teikoku Chem Ind Corp Ltd Preparation of 1-(5'-oxohexyl)-3,7-dimethylxanthine
DE3138397A1 (en) * 1981-09-26 1983-04-07 Hoechst Ag, 6230 Frankfurt "MEDICINAL PRODUCTS CONTAINING VICINALS OF DIHYDROXYALKYLXANTHINE AND PRODUCTION METHOD FOR THESE XANTHINE COMPOUNDS"
US4575795A (en) * 1983-04-01 1986-03-11 Honeywell Information Systems Inc. Apparatus for detecting a predetermined character of a data string

Also Published As

Publication number Publication date
FI89921C (en) 1993-12-10
JPS63501149A (en) 1988-04-28
AU588350B2 (en) 1989-09-14
IE59025B1 (en) 1993-12-15
AU6143986A (en) 1987-02-10
LV5703A3 (en) 1995-02-20
MA20739A1 (en) 1987-04-01
MX9254A (en) 1993-06-01
ES2001019A6 (en) 1988-04-16
BG60767B2 (en) 1996-02-29
KR950001019B1 (en) 1995-02-07
AR244689A1 (en) 1993-11-30
LT3869B (en) 1996-04-25
IL79457A0 (en) 1986-10-31
FI880174A (en) 1988-01-15
HU198486B (en) 1989-10-30
DE3671627D1 (en) 1990-07-05
CA1262248A (en) 1989-10-10
OA08707A (en) 1989-03-31
NO871111L (en) 1987-03-18
NO165803B (en) 1991-01-02
JPH0788382B2 (en) 1995-09-27
GR861866B (en) 1986-11-17
NZ216888A (en) 1989-05-29
EP0268585A1 (en) 1988-06-01
LTIP1467A (en) 1995-05-25
DE3525801A1 (en) 1987-01-22
EP0268585B1 (en) 1990-05-30
DD261156A5 (en) 1988-10-19
PH26262A (en) 1992-04-01
US4833146A (en) 1989-05-23
FI880174A0 (en) 1988-01-15
KR870700623A (en) 1987-12-30
CS272766B2 (en) 1991-02-12
TNSN86111A1 (en) 1990-01-01
DK157867B (en) 1990-02-26
DK157867C (en) 1990-07-30
WO1987000523A3 (en) 1987-02-26
ZA865374B (en) 1987-02-25
DK139287D0 (en) 1987-03-18
NO871111D0 (en) 1987-03-18
CN86105835A (en) 1987-01-14
CS545386A2 (en) 1990-04-11
RU2051918C1 (en) 1996-01-10
DK139287A (en) 1987-03-18
NO165803C (en) 1991-04-10
PT83013A (en) 1986-08-01
PT83013B (en) 1989-01-30
CN1026112C (en) 1994-10-05
HUT47274A (en) 1989-02-28
WO1987000523A2 (en) 1987-01-29
ATE53211T1 (en) 1990-06-15
FI89921B (en) 1993-08-31

Similar Documents

Publication Publication Date Title
IE861917L (en) Tertiary hydroxyalkylxanthines
ZA937780B (en) Substituted benzylaminoquinuclidines
IL65501A (en) 1-alkyl-2-aminotetralin derivatives,process for their preparation and pharmaceutical compositions containing them
ES463036A1 (en) 3,7-Disubstituted-3-cephem-4-carboxylic acid compounds and processes for the preparation thereof
ES8305714A1 (en) Piperidylidene derivatives, their production and pharmaceutical compositions containing them.
MY104335A (en) 4-aminophridine deravatives
ES8305736A1 (en) Pyridazine derivatives active on the central nerve system.
AU6235890A (en) Purification of 1,1-dichloro-1-fluoroethane
ES2006619A6 (en) Bisphenylalkylpiperazine derivatives, a method of their preparation and a pharmaceutical preparation.
MY102003A (en) Novel derivatives of 4, 5-dihydrooxazoles, a process for their preparation, and their use.
DE69103087D1 (en) N-substituted trifluoromethylphenyltetrahydropyridines, processes for their preparation, intermediates and medicaments containing them.
ZA874541B (en) Removal of impurities from hydrocarbon by catalystic hydrogenation(&#34;hytrofining&#34;)and additive for use therewith
HU9400094D0 (en) New 17,20-epoxy-pregnane derivatives process for producing them and use of them for producing cortizone derivatives and intermadeiates
GR77000B (en)
ZA835390B (en) 7-acylthio-15,16-methylene-3-oxo-17-pregna-1,4-diene 21,17-carbolactones,their preparation and use as medicinal agents
ES466245A1 (en) 1,2,3,4,4a,10b-hexahydro-benz(f)isouqinolines
HU9300476D0 (en) Method for producing pharmaceutical preparatives containing xanthine derivatives
GR3000773T3 (en) 2,2;6,6-diethylene-3-oxo-17-alpha-pregn-4-ene-21,17-carbolactones, process for their preparation and pharmaceutical compositions containing them
JPS57108087A (en) (4,5)-4h-benzo(1,2-b)cycloheptafuran derivative, manufacture and use as medicine
EP0196330A1 (en) Use of pyrrothine derivatives.
EP0144441A4 (en) Blood pressure-controlling agent.
JPS544874A (en) Treating method for waste solution containing fluorine and arsenic
UA41309C2 (en) Derivatives of 11-&lt;font face=&#34;Symbol&#34;&gt;b&lt;/font&gt;-benzaldoximextra-4,9-dien , a process for the preparation thereof and a pharmaceutical composition
PT77868B (en) A process for preparing oxanosine and an intermediate used in this process
IL84364A0 (en) 4-hydroxy-4-(substituted alkenyl)-cyclohexanecarboxylic acids,process for their preparation and pharmaceutical compositions containing same

Legal Events

Date Code Title Description
MM4A Patent lapsed